Clinical Trials · NCT00295750
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 620
- Start date
- Feb 2006
- Locations
- 35 sites, 12 countries
- Primary endpoint
- Percentage of Patients With Testosterone <=0.5ng/mL From Day 28 Through Day 364